ARTICLE | Clinical News
Sativex sublingual cannabis extract spray: Completed Phase II/III enrollment
December 7, 2009 8:00 AM UTC
GW completed enrollment of 360 patients in a single and double-blind, placebo-controlled, dose-escalation, international Phase II/III trial evaluating Sativex. Bayer has rights to market Sativex in Ca...